Veryan Medical Ltd.
This article was originally published in Start Up
Executive Summary
While the incorporation of drugs has radically reduced restenosis in coronary stents, it remains a serious issue in other vascular devices. Veryan Medical Ltd. thinks that the problem lies in the limitations of 2-D cylindrical devices to accommodate the natural, 3-D flow of blood. The company is building devices that replicate the swirling flow of blood through the vasculature. That spiral flow flushes out areas of stagnation and prevent the formation of intimal hyperplasia and restenosis.
You may also be interested in...
Edwards: Battling the Innovator's Dilemma
Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.